Statistics from Altmetric.com
In cognitively unimpaired multiple sclerosis patients, a single session of high-frequency repetitive transcranial magnetic stimulation improves working memory performance
The identification of treatment strategies that could ameliorate or even prevent symptom onset and progression in patients with multiple sclerosis (MS) remains a largely unmet need. Several recent studies have consistently demonstrated that modulation of brain functional plasticity within cognitive-related networks by using, for instance, tailored cognitive-rehabilitation procedures can help to restore cognitive abilities.1 In their JNNP paper, Hulst et al2 investigated the effects of a single session of high-frequency repetitive transcranial magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex on working memory performance in 17 MS patients without cognitive impairment. Using the N-back task during functional MRI, they also assessed the consequences of rTMS on the recruitment and connectivity within the working memory network. The two main findings of this study are a significant improvement of N-back task accuracy for higher load conditions following real-rTMS …
Contributors MAR was invited to write the editorial commentary and drafted the manuscript. MF was involved in the discussion and in the manuscript editing.
Competing interests MAR received speakers’ honoraria from Biogen Idec, Novartis, Genzyme, Sanofi-Aventis, Teva Pharmaceutical Industries and Excemed and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla. MF is Editor-in-Chief of the Journal of Neurology; serves on scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Biogen Idec, Excemed, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer's Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.